Electroencephalography and event‐related potentials as biomarkers of mild cognitive impairment and mild Alzheimer's disease

Jackson, Colleen E.; Snyder, Peter J.

doi:10.1016/j.jalz.2007.10.008

Cited by 149 publications

(118 citation statements)

References 58 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…Currently, most functional EEG biomarkers [302] are based on spatio-temporal features such as the peak amplitude or latency of event-related potentials (ERPs) [303] (e.g. the N400/P600 ERPs which are cognitive indicators of episodic memory encoding [304]).…”

Section: Functional Neuroelectrical/neuromagnetic Markersmentioning

confidence: 99%

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Hampel

Lista

Teipel

et al. 2014

Biochemical Pharmacology

102

View full text Add to dashboard Cite

Recent advances in understanding the molecular mechanisms underlying various paths toward the pathogenesis of Alzheimer's disease (AD) has begun to provide new insight for interventions to modify disease progression. The evolving knowledge gained from multidisciplinary basic research has begun to identify new concepts for treatments and distinct classes of therapeutic targets; as well as putative disease-modifying compounds that are now being tested in clinical trials. There is a mounting consensus that such disease modifying compounds and/or interventions are more likely to be effectively administered as early as possible in the cascade of pathogenic processes preceding and underlying the clinical expression of AD. The budding sentiment is that "treatments" need to be applied before various molecular mechanisms converge into an irreversible pathway leading to morphological, metabolic and functional alterations that characterize the pathophysiology of AD. In light of this, biological indicators of pathophysiological mechanisms are desired to chart and detect AD throughout the asymptomatic early molecular stages into the prodromal and early dementia phase. A major conceptual development in the clinical AD research field was the recent proposal of new diagnostic criteria, which specifically incorporate the use of biomarkers as defining criteria for preclinical stages of AD. This paradigm shift in AD definition, conceptualization, operationalization, detection and diagnosis represents novel fundamental opportunities for the modification of interventional trial designs. This perspective summarizes not only present knowledge regarding biological markers but also unresolved questions on the status of surrogate indicators for detection of the disease in asymptomatic people and diagnosis of AD

show abstract

Section: Functional Neuroelectrical/neuromagnetic Markersmentioning

confidence: 99%

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Hampel

Lista

Teipel

et al. 2014

Biochemical Pharmacology

102

View full text Add to dashboard Cite

show abstract

“…In comparison with biochemical or imaging approaches little attention has been paid to the application of electroencephalograms, quantitative electroencephalography (Jackson and Snyder, 2008;Koenig et al, 2005). For example, abnormalities in P600 and N400, two ERP components, have been associated with the conversion from amnestic MCI to AD (Olichney et al, 2008).…”

Section: Neurophysiological Biomarkersmentioning

confidence: 99%

Biomarkers for Alzheimer’s disease and other forms of dementia: Clinical needs, limitations and future aspects

Cedazo-Minguez

Winblad

2010

Experimental Gerontology

136

133

View full text Add to dashboard Cite

To cite this version:Angel Cedazo-Minguez, Bengt Winblad. Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. Experimental Gerontology, Elsevier, 2009, 45 (1), pp. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT

show abstract

“…This paper is one of the few studies in recent years to provide an overview and critical assessment of various state-of-the-art signal processing methods for diagnosing AD from EEG signals (see [15,16,17] for related earlier reviews).…”

Section: Introductionmentioning

confidence: 99%

Diagnosis of Alzheimers Disease from EEG Signals: Where Are We Standing?

Dauwels¹,

Vialatte²,

Cichocki³

2010

CAR

378

188

View full text Add to dashboard Cite

This paper reviews recent progress in the diagnosis of Alzheimer's disease (AD) from electroencephalograms (EEG). Three major effects of AD on EEG have been observed: slowing of the EEG, reduced complexity of the EEG signals, and perturbations in EEG synchrony. In recent years, a variety of sophisticated computational approaches has been proposed to detect those subtle perturbations in the EEG of AD patients. The paper first describes methods that try to detect slowing of the EEG. Next the paper deals with several measures for EEG complexity, and explains how those measures have been used to study fluctuations in EEG complexity in AD patients. Then various measures of EEG synchrony are considered in the context of AD diagnosis.Also the issue of EEG pre-processing is briefly addressed. Before one can analyze EEG, it is necessary to remove artifacts due to for example head and eye movement or interference from electronic equipment. Pre-processing of EEG has in recent years received much attention. In this paper, several state-of-the-art pre-processing techniques are outlined, for example, based on blind source separation and other non-linear filtering paradigms.In addition, the paper outlines opportunities and limitations of computational approaches for diagnosing AD based on EEG. At last, future challenges and open problems are discussed.

show abstract

Electroencephalography and event‐related potentials as biomarkers of mild cognitive impairment and mild Alzheimer's disease

Abstract: As different signature changes associated with particular stages of disease burden are identified and validated, we anticipate expanded application of qEEG as a reliable and sensitive biomarker(s) of MCI and early Alzheimer's disease.

Cited by 149 publications

References 58 publications

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Biomarkers for Alzheimer’s disease and other forms of dementia: Clinical needs, limitations and future aspects

Diagnosis of Alzheimers Disease from EEG Signals: Where Are We Standing?

Contact Info

Product

Resources

About